Saudi Arabia's Pharma Market Is 'Open For Business'
This article was originally published in The Pink Sheet Daily
Growing market is also a gateway to the Gulf region, and Saudi regulators are developing an abridged review process for some drugs already reviewed by agencies such as FDA or EMA.
You may also be interested in...
A new abridged drug review system in Saudi Arabia will dramatically cut the time it takes to get a new product to market in Saudi Arabia. The new system, which will go live in February 2017, could have a knock on effect on market access in neighboring markets.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.